These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1869100)

  • 61. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic implications of large volume residual disease in patients with advanced stage epithelial ovarian cancer.
    Gallion HH; van Nagell JR; Donaldson ES; Hanson MB; Kryscio RJ
    Gynecol Oncol; 1987 Jun; 27(2):220-5. PubMed ID: 3570060
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: a Southwest Oncology Group Study.
    Alberts DS; Mason-Liddil N; O'Toole RV; Abbott TM; Kronmal R; Hilgers RD; Surwit EA; Eyre HJ; Baker LH
    Gynecol Oncol; 1989 Jan; 32(1):8-15. PubMed ID: 2642455
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
    Baker TR; Piver MS; Hempling RE
    Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Results of a Southwest Oncology Group phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer.
    Hannigan EV; Green S; Alberts DS; O'Toole R; Surwit E
    Oncology; 1993 Nov; 50 Suppl 2():2-9. PubMed ID: 8233297
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combination chemotherapy in the management of ovarian germ cell malignancies.
    Schwartz PE
    Obstet Gynecol; 1984 Oct; 64(4):564-72. PubMed ID: 6207473
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combination chemotherapy in advanced ovarian carcinoma.
    Amadori D; Ravaioli A; Maltoni M; Ridolfi R; Gentilini P; Giunchi DC; Frassineti L; Falcini F; Amadori M
    Tumori; 1986 Oct; 72(5):519-24. PubMed ID: 3798574
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin.
    Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Greenspan EM; Gusberg SB; Holland JF
    Cancer; 1981 May; 47(9):2288-94. PubMed ID: 6784917
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
    Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
    Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
    Tangir J; Zelterman D; Ma W; Schwartz PE
    Obstet Gynecol; 2003 Feb; 101(2):251-7. PubMed ID: 12576247
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group.
    Feld R; Rubinstein L; Thomas PA
    J Natl Cancer Inst; 1993 Feb; 85(4):299-306. PubMed ID: 8381187
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung.
    Davis S; Rambotti P; Park YK
    Cancer Treat Rep; 1981; 65(11-12):955-8. PubMed ID: 7028257
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
    Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
    Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Drug therapy of ovarian carcinoma].
    Dittrich C
    Wien Med Wochenschr; 1996; 146(1-2):23-34. PubMed ID: 8835492
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin- and cis-platinum-based chemotherapy.
    Plaxe SC; Dottino PR; Goodman HM; Deligdisch L; Idelson M; Cohen CJ
    Gynecol Oncol; 1990 May; 37(2):244-9. PubMed ID: 2160905
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study.
    Bolis G; Bortolozzi G; Carinelli G; D'Incalci M; Gramellini F; Morasca L; Mangioni C
    Cancer Chemother Pharmacol; 1980; 4(2):129-32. PubMed ID: 7389058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.